Innovent Biologics to sell a 3.87% stake to French pharmaceutical giant in pact to collaborate in developing two new cancer treatments

Cancer drug maker joins parade of pre-profit biotech IPOs in face of declining global markets

Cancer treatment developer is the latest to weigh listing in Hong Kong under rules revised to attract early-stage biotech listings

New funding values maker of new group of cancer drugs at more than $1 billion

Chinese firm resubmits application to launch innovative lymphoma treatment

Next step is to list in New York or Hong Kong as company moves closer to releasing China’s first immunotherapy for cancer